Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
44 hedge funds and large institutions have $23.5M invested in Northwest Biotherapeutics, Inc. Common stock in 2013 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 13 increasing their positions, 2 reducing their positions, and 3 closing their positions.
567% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 3
550% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 2
63% more funds holding
Funds holding: 27 → 44 (+17)
39% more capital invested
Capital invested by funds: $16.8M → $23.5M (+$6.63M)
82% less call options, than puts
Call options by funds: $180K | Put options by funds: $1.02M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$2.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.32M |
| 3 |
WA
Whitebox Advisors
Minneapolis,
Minnesota
|
+$1.03M |
| 4 |
BFIC
Bedell Frazier Investment Counselling
Walnut Creek,
California
|
+$440K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$426K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$3.79M |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
-$111K |
| 3 |
CL
Croft-Leominster
Baltimore,
Maryland
|
-$38.7K |
| 4 |
Barclays
London,
United Kingdom
|
-$7K |
| 5 |
KA
Kovack Advisors
Ft. Lauderdale,
Florida
|
-$2.86K |
NWBO Hedge Fund Activity: Q4 2013 in Review
44 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q4 2013, worth a combined $23.5M — up 39% from $16.8M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new NWBO positions and 3 closed out — a net gain of 17 holders — while 13 added to existing stakes and 2 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $2.4M. The largest seller was Sabby Management, exiting entirely with an estimated $3.79M sold.
- 44 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q4 2013, up from 27 in Q3 2013.
- Funds reported $23.5M of Northwest Biotherapeutics, Inc. Common stock stock for Q4 2013, up 39% quarter-over-quarter.
- 20 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q4 2013 and 3 closed out, a net change of +17 holders.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q4 2013 was Goldman Sachs, an estimated $2.4M added.
- The largest Northwest Biotherapeutics, Inc. Common stock seller in Q4 2013 was Sabby Management, an estimated $3.79M sold.
Based on aggregated 13F filings for Q4 2013.